ulipristal acetate · Lab Hra Pharma · NDA 022474
Ella
Earliest generic entry, as listed
12 Jun 2030
Blocked by patent: US 8426392, US 8962603. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 8 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8426392 | use U-1389 | 12 Jun 2030 |
| US 8962603 | use U-1657 | 12 Jun 2030 |
| US 8512745 | product | 2 Jun 2030 |
| US 10159681 | use U-2510 | 13 Apr 2030 |
| US 10772897 | use U-2958 | 13 Apr 2030 |
| US 9283233 | use U-1821 | 13 Apr 2030 |
| US 8735380 | product | 20 Feb 2029 |
| US 9844510 | product | 8 Dec 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022474 · 001 · RLD | tablet, oral | 30MG | 12 Jun 2030 |